Maplight Therapeutics (NASDAQ:MPLT) Insider Sells $93,025.04 in StockDefense World · 6 days ago
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Insider Sells $96,024.32 in StockDefense World · 6 days ago
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Insider Sells $124,068.40 in StockDefense World · 6 days ago
Maplight Therapeutics (NASDAQ:MPLT) CFO Sells $82,149.36 in StockDefense World · 6 days ago
Down 29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in MapLight Therapeutics, Inc. (MPLT)Zacks Investment Research · Oct 16, 2026
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Stock Has Consensus Price Target of $29.50Defense World · Oct 16, 2026MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease.
| Date | Est. | Actual | |
|---|---|---|---|
| Sep 18, 2026 | -$1.35 | -$1.32 | Beat |
| Aug 13, 2026 | -$1.35 | -$1.32 | Beat |
| May 15, 2026 | -$1.05 | -$1.34 | Miss |
| Dec 4, 2025 | -$1.72 | -$37.18 | Miss |
| Aug 22, 2025 | -$0.96 | -$1.14 | Miss |
| Jul 30, 2025 | – | -$0.54 |